AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Cystic Fibrosis Pipeline Review, H2 2019 - Analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type - ResearchAndMarkets.com

December 3, 2019

DUBLIN--(BUSINESS WIRE)--Dec 3, 2019--

The “Cystic Fibrosis - Pipeline Review, H2 2019” drug pipelines has been added to ResearchAndMarkets.com’s offering.

This report provides an overview of the Cystic Fibrosis (Respiratory) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cystic Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cystic Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Cystic Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 34, 18, 66 and 33 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical, Discovery and Unknown stages comprises 2, 1, 10, 9 and 1 molecules, respectively.

Cystic Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Report Scope

Reasons to Buy

Key Topics Covered

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/g1ciqn

View source version on businesswire.com:https://www.businesswire.com/news/home/20191203006083/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 12/03/2019 05:21 PM/DISC: 12/03/2019 05:21 PM

http://www.businesswire.com/news/home/20191203006083/en